Soil and bee gut
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA505714 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Explorative description of the gut microbiota of Apis mellifera ligustica. the study aims at describing the diverse fractions of the microbial community including bacteria, fungi, unicellular parasites
2024-06-16 | PXD043896 | Pride
Project description:Reference database genomes of bee gut bacteria
| PRJNA471810 | ENA
Project description:16S rRNA of targeted modified human gut microbiotas
| PRJNA655374 | ENA
Project description:Morphine and its pharmacological derivatives are the most prescribed analgesics for moderate to severe pain management. However, chronic use of morphine reduces pathogen clearance and induces bacterial translocation across the gut barrier. The enteric microbiome has been shown to play a critical role in the preservation of the mucosal barrier function and metabolic homeostasis. Here, we show for the first time, using bacterial 16s rDNA sequencing, that chronic morphine treatment significantly alters the gut microbial composition and induces preferential expansion of the gram-positive pathogenic and reduction of bile-deconjugating bacterial strains. A significant reduction in both primary and secondary bile acid levels was seen in the gut, but not in the liver with morphine treatment. Morphine induced microbial dysbiosis and gut barrier disruption was rescued by transplanting placebo-treated microbiota into morphine-treated animals, indicating that microbiome modulation could be exploited as a therapeutic strategy for patients using morphine for pain management. In this study, we establish a link between the two phenomena, namely gut barrier compromise and dysregulated bile acid metabolism. We show for the first time that morphine fosters significant gut microbial dysbiosis and disrupts cholesterol/bile acid metabolism. Changes in the gut microbial composition is strongly correlated to disruption in host inflammatory homeostasis13,14 and in many diseases (e.g. cancer/HIV infection), persistent inflammation is known to aid and promote the progression of the primary morbidity. We show here that chronic morphine, gut microbial dysbiosis, disruption of cholesterol/bile acid metabolism and gut inflammation; have a linear correlation. This opens up the prospect of devising minimally invasive adjunct treatment strategies involving microbiome and bile acid modulation and thus bringing down morphine-mediated inflammation in the host.
2016-06-01 | E-MTAB-3722 | biostudies-arrayexpress
Project description:Significant gut microbiota heterogeneity exists amongst UC patients though the clinical implications of this variance are unknown. European and South Asian UC patients exhibit distinct disease risk alleles, many of which regulate immune function and relate to variation in gut microbiota β-diversity. We hypothesized ethnically distinct UC patients exhibit discrete gut microbiotas with unique luminal metabolic programming that influence adaptive immune responses and relate to clinical status. Using parallel bacterial 16S rRNA and fungal ITS2 sequencing of fecal samples (UC n=30; healthy n=13), we corroborated previous observations of UC-associated depletion of bacterial diversity and demonstrated significant gastrointestinal expansion of Saccharomycetales as a novel UC characteristic. We identified four distinct microbial community states (MCS 1-4), confirmed their existence using microbiota data from an independent UC cohort, and show they co-associate with patient ethnicity and degree of disease severity. Each MCS was predicted to be uniquely enriched for specific amino acid, carbohydrate, and lipid metabolism pathways and exhibited significant luminal enrichment of metabolic products from these pathways. Using a novel in vitro human DC/T-cell assay we show that DC exposure to patient fecal water led to MCS -specific changes in T-cell populations, particularly the Th1:Th2 ratio, and that patients with the most severe disease exhibited the greatest Th2 skewing. Thus, based on ethnicity, microbiome composition, and associated metabolic dysfunction, UC patients may be stratified in a clinically and immunologically meaningful manner, providing a platform for the development of FMC-focused therapy. Fecal microbiome was assessed with Affymetrix PhyloChip arrays from patients with ulcerative colitis and healthy controls.
2016-07-25 | E-GEOD-78724 | biostudies-arrayexpress
Project description:Some therapeutic compounds can influence our gut microbiota, but a comprehensive understanding of their impact on microbial systems ecology remains largely unexplored. This study examines the impact of 312 therapeutic compounds on metaproteomes of six ex vivo human gut microbiota, generating 4.6 million microbial protein responses, available as an interactive resource. Further data analysis discovered that 15% of the compounds induced consistent functional changes across microbiotas, with neuropharmaceuticals being significantly enriched. These neuropharmaceuticals induced profound metaproteomic alterations, along with community-level functional redundancy (FR) decrease and antimicrobial resistance protein (ARP) increase. Two functional states in the metaproteomic response landscape were observed: one with high FR and low ARP, and another with decreased FR and induced ARP. Based on the energy landscape principle, we validated that enhancing FR maintained a microbiota’s resilience against neuropharmaceutical-induced ARP increase. Our results highlight a novel strategy to counter drug-induced negative impacts by leveraging the functional landscape.
2025-08-28 | PXD056968 | Pride
Project description:Some therapeutic compounds can influence our gut microbiota, but a comprehensive understanding of their impact on microbial systems ecology remains largely unexplored. This study examines the impact of 312 therapeutic compounds on metaproteomes of six ex vivo human gut microbiota, generating 4.6 million microbial protein responses, available as an interactive resource. Further data analysis discovered that 15% of the compounds induced consistent functional changes across microbiotas, with neuropharmaceuticals being significantly enriched. These neuropharmaceuticals induced profound metaproteomic alterations, along with community-level functional redundancy (FR) decrease and antimicrobial resistance protein (ARP) increase. Two functional states in the metaproteomic response landscape were observed: one with high FR and low ARP, and another with decreased FR and induced ARP. Based on the energy landscape principle, we validated that enhancing FR maintained a microbiota’s resilience against neuropharmaceutical-induced ARP increase. Our results highlight a novel strategy to counter drug-induced negative impacts by leveraging the functional landscape.
2025-08-28 | PXD056888 | Pride
Project description:Some therapeutic compounds can influence our gut microbiota, but a comprehensive understanding of their impact on microbial systems ecology remains largely unexplored. This study examines the impact of 312 therapeutic compounds on metaproteomes of six ex vivo human gut microbiota, generating 4.6 million microbial protein responses, available as an interactive resource. Further data analysis discovered that 15% of the compounds induced consistent functional changes across microbiotas, with neuropharmaceuticals being significantly enriched. These neuropharmaceuticals induced profound metaproteomic alterations, along with community-level functional redundancy (FR) decrease and antimicrobial resistance protein (ARP) increase. Two functional states in the metaproteomic response landscape were observed: one with high FR and low ARP, and another with decreased FR and induced ARP. Based on the energy landscape principle, we validated that enhancing FR maintained a microbiota’s resilience against neuropharmaceutical-induced ARP increase. Our results highlight a novel strategy to counter drug-induced negative impacts by leveraging the functional landscape.
2025-08-28 | PXD056930 | Pride
Project description:Masai Mara herbivore gut microbiotas Raw sequence reads
| PRJNA656793 | ENA
Project description:honey bee gut microbiome Raw sequence reads
| PRJNA640152 | ENA